Several biotechnology companies have released their financial results for the full year 2024. Abivax Inc. reported its financial outcomes under the ticker $ABVX. Lexeo Therapeutics Inc., under the ticker $LXEO, disclosed its fourth quarter and full year financial results along with operational highlights. Larimar Therapeutics Inc. provided an update on Nomlabofusp development and reported its financial results for the fourth quarter and full year under the ticker $LRMR. Centessa Pharmaceuticals plc shared its business highlights and financial results for the fourth quarter and full year under the ticker $CNTA. Moleculin Biotech Inc. reported its full year financial results and provided a corporate update under the ticker $MBRX. Clene Inc. reported its full year financial results and recent operating highlights under the ticker $CLNN. Salarius Pharmaceuticals Inc. reported its 2024 financial results and provided a business update under the ticker $SLRX. Adagene Inc. reported its full year financial results and provided a corporate update under the ticker $ADAG. Aura Biosciences Inc. reported its fourth quarter and full year financial results along with business highlights under the ticker $AURA. Artiva Biotherapeutics Inc. reported its full year financial results and recent business highlights under the ticker $ARTV. NEXGEL Inc. reported record fourth quarter and full year financial results under the ticker $NXGL. Quince Therapeutics Inc. provided a business update and reported its fiscal year 2024 financial results under the ticker $QNCX. Serina Therapeutics Inc. reported its full year financial results and recent business highlights under the ticker $SER. Lucid Diagnostics Inc., under the ticker $LUCD, reported its business update and financial results for the fourth quarter and full year 2024. The company processed a record 4,042 EsoGuard tests in the fourth quarter of 2024, marking a 45% sequential and 84% annual increase. Lucid Diagnostics also secured its first agreement to pay for EsoGuard under state biomarker legislation and generated over 20 new cash-pay concierge medicine contracts through a new sales channel. KB Home, under the ticker $KBH, reported its first quarter 2025 earnings, showing a revenue of $1.39 billion, down 5% from the previous year. The company delivered 2,770 homes, a decrease of 9%, while the average selling price rose 4% to $500,700. Homebuilding operating income was $127.3 million, compared to $157.7 million the previous year. KB Home's earnings per share were $1.49, missing the estimate of $1.70, and its revenue of $1.39 billion fell short of the $1.50 billion estimate. The company revised its full-year 2025 revenue guidance to $6.6 billion to $7.0 billion, down from the prior range of $7.0 billion to $7.5 billion. Oklo Inc., under the ticker $OKLO, reported its full year 2024 financial results, showing a loss of 74 cents per share and operating losses totaling $52.8 million. The company's cash used in operations for the full year was $38.4 million, which was below the forecasted range of $40 million to $50 million. Share prices of Oklo slid in response to the earnings report. Intuitive Machines Inc., under the ticker $LUNR, reported triple revenue growth and a $328 million backlog. Despite a troubled moon landing, the company's backlog suggests potential for future growth.